Whole Brain Radiotherapy Combined with Temozolomide in the Treatment of 30 Cases with Brain Metastasis from Nonsmall Cell Lung Cancer
SUN Zong-wen;ZHANG Yan;The First People's Hospital of Jining City;
[Purpose] To investigate the therapeutic effect,survival and toxicity of whole brain radiotherapy alone or radiotherapy combined with temozolomide(TMZ) in the treatment of brain metastases from non-small cell lung cancer(NSCLC). [Methods] Sixty NSCLC patients with brain metastasis were randomly divided into radiotherapy group(30 cases) and chemoradiotherapy group(combination group,30 cases):radiotherapy group with whole brain conventional radiotherapy dose DT40Gy/20F/4W;combination group with the same radiation method as the radiotherapy group,concurrent with TMZ dose of 75 mg/(m2·d),d1~28. [Results] The response rate of radiotherapy group and combination group was 43.3%(13/30) and 63.3%(19/30)(P=0.07) respectively;and the median survival was 4.3 months and 8.5 months(P0.01) respectively. Bone marrow suppression and gastrointestinal toxicities in combination group were higher than those in the radiotherapy group(P0.05). [Conclusion] Whole brain radiotherapy combined with TMZ might be used as a treatment option for NSCLC patients with brain metastasis,with tolerable toxicities.